Previous studies have established that SMARCA2 deficiency is a pathognomonic genomic driver in high-grade clear cell renal cell carcinoma (ccRCC), mechanistically linked to epigenetic reprogramming that fuels sarcomatoid differentiation (17). This evidence concerns the gene SMARCA2 and nonpapillary renal cell carcinoma.